MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering price of $1.1099 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.0001 per share exercise price. The gross proceeds to TELA from the offering, before deducting underwriting discounts and estimated offering expenses, are expected to be approximately $13.0 million, assuming no exercise of the pre-funded warrants. The offering is expected to close on or about November 17, 2025, subject to the satisfaction of customary closing conditions.

The offering was led by Nantahala Capital and EW Healthcare Partners.

Canaccord Genuity is acting as the sole bookrunner for the offering.

TELA intends to use the net proceeds from the offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures.

The offering is being made pursuant to a shelf registration ...